KR102355106B1 - Pharmaceutical and functional food composition comprising complex extract of Platycodon grandiflorus for prevention or treatment of respiratory disease - Google Patents
Pharmaceutical and functional food composition comprising complex extract of Platycodon grandiflorus for prevention or treatment of respiratory disease Download PDFInfo
- Publication number
- KR102355106B1 KR102355106B1 KR1020200028725A KR20200028725A KR102355106B1 KR 102355106 B1 KR102355106 B1 KR 102355106B1 KR 1020200028725 A KR1020200028725 A KR 1020200028725A KR 20200028725 A KR20200028725 A KR 20200028725A KR 102355106 B1 KR102355106 B1 KR 102355106B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- bellflower
- honey
- licorice
- chrysanthemum
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 136
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 244000274050 Platycodon grandiflorum Species 0.000 title claims description 7
- 235000006753 Platycodon grandiflorum Nutrition 0.000 title claims description 6
- 235000013376 functional food Nutrition 0.000 title claims description 4
- 208000023504 respiratory system disease Diseases 0.000 title abstract description 21
- 238000011282 treatment Methods 0.000 title abstract description 12
- 230000002265 prevention Effects 0.000 title abstract description 11
- 241000332371 Abutilon x hybridum Species 0.000 claims abstract description 89
- 239000000428 dust Substances 0.000 claims abstract description 28
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 6
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 150
- 235000012907 honey Nutrition 0.000 claims description 78
- 240000005250 Chrysanthemum indicum Species 0.000 claims description 77
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 73
- 241000202807 Glycyrrhiza Species 0.000 claims description 73
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 73
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 73
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 73
- 229940010454 licorice Drugs 0.000 claims description 73
- 230000002829 reductive effect Effects 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 5
- 235000018959 Chrysanthemum indicum Nutrition 0.000 claims description 4
- 240000008917 Glycyrrhiza uralensis Species 0.000 claims description 4
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 6
- 230000000052 comparative effect Effects 0.000 description 43
- 238000002360 preparation method Methods 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000010438 heat treatment Methods 0.000 description 15
- 239000008213 purified water Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- -1 analgesic Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940069445 licorice extract Drugs 0.000 description 5
- 230000006433 tumor necrosis factor production Effects 0.000 description 5
- 206010014561 Emphysema Diseases 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000000954 anitussive effect Effects 0.000 description 4
- 229940124584 antitussives Drugs 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 230000021995 interleukin-8 production Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 3
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 3
- 206010006458 Bronchitis chronic Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 208000007451 chronic bronchitis Diseases 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 206010038678 Respiratory depression Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 201000009267 bronchiectasis Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 231100000065 noncytotoxic Toxicity 0.000 description 2
- 230000002020 noncytotoxic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- GPESMPPJGWJWNL-UHFFFAOYSA-N azane;lead Chemical compound N.[Pb] GPESMPPJGWJWNL-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000009520 bofu-tsusho-san Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- TXKMVPPZCYKFAC-UHFFFAOYSA-N disulfur monoxide Inorganic materials O=S=S TXKMVPPZCYKFAC-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 229920005547 polycyclic aromatic hydrocarbon Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019997 soju Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical compound S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 도라지 유효성분을 포함한 천연물 추출물을 유효성분으로 하는 미세먼지 관련 호흡기 질환의 예방 및 치료용 약학적 조성물 및 식품 조성물에 관한 것으로, 본 발명에 따르면, 도라지와 감초와 감국 및 꿀 복합 추출물은 미세먼지에 의한 NO 생성을 억제하고, 염증성 사이토카인 IL-8과 TNF-α의 생성을 억제하는 효과를 나타내는 바, 미세먼지 관련 호흡기 질환의 예방 및 치료용 약학적 조성물 및 식품 조성물 등으로 유용하게 활용될 수 있다.The present invention relates to a pharmaceutical composition and a food composition for the prevention and treatment of respiratory diseases related to fine dust, comprising a natural extract including an active ingredient of bellflower as an active ingredient. It suppresses NO production by fine dust and shows the effect of inhibiting the production of inflammatory cytokines IL-8 and TNF-α, so it is useful as a pharmaceutical composition and food composition for the prevention and treatment of fine dust-related respiratory diseases can be utilized.
Description
본 발명은 도라지 유효성분을 포함한 천연물 추출물을 유효성분으로 하는 미세먼지 관련 호흡기 질환 예방 및 치료용 식품 조성물 및 그의 제조 방법에 관한 것으로서, 본 발명에 따른 조성물은 미세먼지에 의한 호흡기 질환의 예방 또는 치료용 식품 조성물로 이용될 수 있다. The present invention relates to a food composition for the prevention and treatment of fine dust-related respiratory diseases and a method for manufacturing the same, comprising a natural extract containing a bellflower active ingredient as an active ingredient, and the composition according to the present invention prevents or treats respiratory diseases caused by fine dust It can be used as a food composition for
미세먼지(Particulate Matter, PM)란 공기 중 장기간 떠다니는 미세한 먼지를 말하며, 입경 2.5 ㎛ 이하의 크기는 초미세먼지로 분류된다. 지난 수십 년간 우리나라의 급격한 산업화 및 공업화로 인해 환경이 지속적으로 악화되어 왔으며, 최근 중국의 높은 석탄 의존도와 급격한 경제 성장과 더불어 스모그 현상이 지속적으로 증가하여 미세먼지의 발생이 빈번해지고 있다. 황산화물, 질소산화물, 납 등의 유해물질들이 포함된 미세먼지는 호흡기 및 피부를 통해 인체 내에 침투할 수 있으며, 폐기능 감소, 천식 악화, 만성기관지염 발생 등 호흡기계 관련 질환을 야기하며, 심근경색, 협심증, 부정맥 등 심혈관계 관련 질환의 발생을 증가시키는 것으로 알려져 있다(김오식 외, 2009, ReSEAT 분석보고서). Particulate Matter (PM) refers to fine dust that floats in the air for a long time, and particles with a particle diameter of 2.5 μm or less are classified as ultra-fine dust. The environment has been continuously deteriorating due to rapid industrialization and industrialization of Korea for the past several decades. Fine dust containing harmful substances such as sulfur oxide, nitrogen oxide, and lead can penetrate into the human body through the respiratory tract and skin, and cause respiratory system-related diseases such as decreased lung function, worsening of asthma, and chronic bronchitis, and myocardial infarction. , is known to increase the incidence of cardiovascular-related diseases, such as angina pectoris and arrhythmia (Oshik Kim et al., 2009, ReSEAT Analysis Report).
미세먼지에 포함된 다환방향족탄화수소(polycyclic aromatic hydrocarbon, PAH)는 세포 내로 침투되어 공통적으로 아릴 하이드로카본 수용체(Aryl hydrocarbon receptor; AhR)를 활성화 시키는 것으로 알려져 있다. AhR 활성화 기전을 통해 세포 내 활성 산소종(Reactive oxygen species; ROS)이 증가되고, 다양한 염증 매개 인자의 발현을 증가시켜 호흡기 질환을 일으키게 된다.It is known that polycyclic aromatic hydrocarbon (PAH) contained in fine dust penetrates into cells and commonly activates Aryl hydrocarbon receptor (AhR). Reactive oxygen species (ROS) in cells is increased through the AhR activation mechanism, and the expression of various inflammatory mediators is increased to cause respiratory diseases.
전세계적으로 미세먼지에 대한 호흡기 질환의 증가에 따라 세계보건기구(WHO)에서는 2013년 1군 발암물질로 분류하였으며, 우리나라도 그에 맞게 미세먼지 저감 방안 및 치료제 개발이 절실한 상황이다. 대부분의 호흡기 질환 치료제는 단일 성분의 합성 의약품으로, 미세먼지의 경우 종래 성분들이 지역적, 계절적, 시기적, 기후 환경적인 영향에 따라 달라지므로, 다양한 병리 기전에 대한 효과적인 치료가 어렵다는 문제점이 있다. 따라서 미세먼지의 발생빈도가 점차 증가되고 있는 사회적 현상으로 인해 치료제 개발 및 연구가 중요하다고 할 수 있다.Due to the increase in respiratory diseases caused by fine dust worldwide, the World Health Organization (WHO) classified it as a group 1 carcinogen in 2013, and Korea is in dire need of measures to reduce fine dust and develop therapeutic agents accordingly. Most respiratory disease treatments are single-component synthetic pharmaceuticals, and in the case of fine dust, conventional components vary depending on regional, seasonal, seasonal, climatic and environmental influences, so there is a problem in that it is difficult to effectively treat various pathological mechanisms. Therefore, it can be said that the development and research of therapeutic agents is important due to a social phenomenon in which the frequency of occurrence of fine dust is gradually increasing.
한편, 도라지(Platycodon grandiflorus)는 뿌리는 식용하고, 한방에서는 도라지를 길경이라고도 하며 신경통과 편도선염 등의 약재로 사용한다. 도라지 뿌리는 사포닌이 많이 포함되어 있어서 생약으로 이용되고 있다. 그밖에도 도리지 뿌리에는 칼슘, 섬유질, 철분, 무기질, 단백질, 비타민 등이 함유되어 있다. 생약은 뿌리가 굵고 내부가 충실하고, 맛이 강한 것이 우량품이다. 거담, 진해, 진통, 진정, 해열 작용이 있으며, 소염진통, 진해거담제로 사용된다. 또한 콜레스테롤을 저하시키는 효능이 있어 혈관계 질환 및 고혈압에도 효과가 있다. 도라지는 호흡기 질환이라 할 수 있는 감기는 물론 천식에도 탁월한 효능을 보이기 때문에 호흡기 질환에 노출되기 쉬운 면역력이 약한 어린아이나 노인, 그리고 잦은 스트레스로 인해서 면역력이 약해진 사람에게 좋다. 주된 산지는 한국, 북한, 중국이다. 도라지탕이나 십미패독탕, 방풍통성산, 배농산 등의 한방재로 사용된다.On the other hand, the root of bellflower ( Platycodon grandiflorus ) is edible, and in oriental medicine, bellflower is also called gilgyeong, and is used as medicine for neuralgia and tonsillitis. Bellflower root contains a lot of saponins, so it is used as a herbal medicine. In addition, doji root contains calcium, fiber, iron, minerals, protein, and vitamins. A crude drug is a quality product with a thick root, a solid inside, and a strong taste. It has expectorant, antitussive, analgesic, sedative, and antipyretic action, and is used as an anti-inflammatory analgesic and antitussive expectorant. It also has the effect of lowering cholesterol, so it is effective in vascular diseases and high blood pressure. Bellflower is excellent for asthma as well as colds, which can be called respiratory diseases, so it is good for children or the elderly with weakened immunity who are easily exposed to respiratory diseases, and for those who have weakened immunity due to frequent stress. The main production areas are South Korea, North Korea and China. It is used as an herbal remedy for bellflower soup, sipmi padoktang, bangpungtongseongsan, and baenongsan.
또한 도라지 추출물 이외의 천연물의 유익한 성분들을 이용하여 기능성식품 등을 제공함으로써 사회적인 문제로 부상되고 있는 미세먼지에 의해 야기되는 호흡기 질환을 예방 및 치료할 필요성이 있다.In addition, there is a need to prevent and treat respiratory diseases caused by fine dust, which is emerging as a social problem, by providing functional foods using beneficial ingredients of natural products other than bellflower extract.
본 발명의 목적은 도라지, 감초, 감국 및 꿀을 포함하는 혼합물을 추출한 추출물을 유효성분으로 하는 미세먼지에 의해 유도된 호흡기 질환의 예방 및 치료용 약학적 조성물 및 식품 조성물을 제공한다. An object of the present invention is to provide a pharmaceutical composition and a food composition for the prevention and treatment of respiratory diseases induced by fine dust, comprising an extract extracted from a mixture containing bellflower, licorice, chrysanthemum and honey as an active ingredient.
본 발명은 상기 목적을 이루기 위하여, 도라지, 감초, 감국 및 꿀을 포함하는 혼합물을 추출한 추출물을 유효성분으로 하는 미세먼지에 의해 유도된 호흡기 질환의 예방 및 치료용 약학적 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention and treatment of respiratory diseases induced by fine dust, comprising an extract extracted from a mixture containing bellflower, licorice, chrysanthemum and honey as an active ingredient.
상기 혼합물은 도라지 100중량부에 대하여 감초 0.1~100 중량부, 감국 0.1~100 중량부 및 꿀 0.1~100 중량부로 혼합되는 것일 수 있다.The mixture may be mixed with 0.1-100 parts by weight of licorice, 0.1-100 parts by weight of chrysanthemum, and 0.1-100 parts by weight of honey, based on 100 parts by weight of bellflower.
상기 추출물은 물, C1 내지 C4의 저급알코올, 에틸아세테이트, 아세톤, 헥산, 디클로로메탄 또는 이들의 혼합용매로 추출된 것일 수 있다.The extract may be extracted with water, C1 to C4 lower alcohol, ethyl acetate, acetone, hexane, dichloromethane, or a mixed solvent thereof.
상기 혼합물에 도라지 100중량부에 대하여 감초 0.1~100 중량부, 감국 0.1~100 중량부 및 꿀 0.1~100 중량부를 더 포함하는 것일 수 있다.0.1-100 parts by weight of licorice, 0.1-100 parts by weight of chrysanthemum, and 0.1-100 parts by weight of honey based on 100 parts by weight of bellflower in the mixture.
상기 호흡기 질환은 호흡기 염증성 폐 질환, 만성 폐쇄성 폐질환 (Chronic Obstructive Pulmonary Disease; COPD), 부비강염, 알레르기성 비염, 하기도 감염증, 급만성기관지염, 폐기종, 폐렴, 기관지 천식, 기관지 확장증, 폐기종, 폐결핵 후유증, 급성 호흡 궁박증후군(窮迫症候群), 낭포성 섬유증, 중이염 및 폐섬유증으로 이루어진 군으로부터 선택되는 하나 이상의 질환일 수 있다.The respiratory disease is respiratory inflammatory lung disease, chronic obstructive pulmonary disease (COPD), sinusitis, allergic rhinitis, lower respiratory tract infection, acute chronic bronchitis, emphysema, pneumonia, bronchial asthma, bronchiectasis, emphysema, sequelae of pulmonary tuberculosis, It may be one or more diseases selected from the group consisting of acute respiratory depression syndrome (窮迫症候群), cystic fibrosis, otitis media, and pulmonary fibrosis.
본 발명은 상기 또 다른 목적을 이루기 위하여 도라지, 감초, 감국 및 꿀을 포함하는 혼합물을 추출한 추출물을 유효성분으로 하는 미세먼지에 의해 유도된 호흡기 질환의 예방 및 치료용 식품 조성물을 제공한다.In order to achieve the above another object, the present invention provides a food composition for the prevention and treatment of respiratory diseases induced by fine dust, comprising an extract extracted from a mixture containing bellflower, licorice, chrysanthemum and honey as an active ingredient.
상기 혼합물은 도라지 100중량부에 대하여 감초 0.1~100 중량부, 감국 0.1~100 중량부 및 꿀 0.1~100 중량부로 혼합되는 것일 수 있다.The mixture may be mixed with 0.1-100 parts by weight of licorice, 0.1-100 parts by weight of chrysanthemum, and 0.1-100 parts by weight of honey, based on 100 parts by weight of bellflower.
상기 추출물은 물, C1 내지 C4의 저급알코올, 에틸아세테이트, 아세톤, 헥산, 디클로로메탄 또는 이들의 혼합용매로 추출된 것일 수 있다.The extract may be extracted with water, C1 to C4 lower alcohol, ethyl acetate, acetone, hexane, dichloromethane, or a mixed solvent thereof.
상기 혼합물에 도라지 100중량부에 대하여 감초 0.1~100 중량부, 감국 0.1~100 중량부 및 꿀 0.1~100 중량부를 더 포함하는 것일 수 있다.0.1-100 parts by weight of licorice, 0.1-100 parts by weight of chrysanthemum, and 0.1-100 parts by weight of honey based on 100 parts by weight of bellflower in the mixture.
상기 호흡기 질환은 호흡기 염증성 폐 질환, 만성 폐쇄성 폐질환 (Chronic Obstructive Pulmonary Disease; COPD), 부비강염, 알레르기성 비염, 하기도 감염증, 급만성기관지염, 폐기종, 폐렴, 기관지 천식, 기관지 확장증, 폐기종, 폐결핵 후유증, 급성 호흡 궁박증후군(窮迫症候群), 낭포성 섬유증, 중이염 및 폐섬유증으로 이루어진 군으로부터 선택되는 하나 이상의 질환일 수 있다.The respiratory disease is respiratory inflammatory lung disease, chronic obstructive pulmonary disease (COPD), sinusitis, allergic rhinitis, lower respiratory tract infection, acute chronic bronchitis, emphysema, pneumonia, bronchial asthma, bronchiectasis, emphysema, sequelae of pulmonary tuberculosis, It may be one or more diseases selected from the group consisting of acute respiratory depression syndrome (窮迫症候群), cystic fibrosis, otitis media, and pulmonary fibrosis.
본 발명에 따르면, 도라지, 감초, 감국 및 꿀을 포함하는 혼합물을 추출한 추출물을 유효성분으로 하는 호흡기 질환 개선 및 치료용 조성물에 관한 것으로, 미세먼지에 의해 유발되는 폐의 염증을 완화시켜주며, 안정성이 뛰어나면서도 경제성이 있는 천연 기능성 소재로서, 의약품, 식품 분야에서의 소재로 활용이 가능하다.According to the present invention, there is provided a composition for improving and treating respiratory diseases using an extract extracted from a mixture containing bellflower, licorice, chrysanthemum and honey as an active ingredient, which relieves inflammation of the lungs caused by fine dust, and stability As this excellent and economical natural functional material, it can be used as a material in the pharmaceutical and food fields.
도 1은 도라지 추출물, 감초 추출물, 감국 추출물, 꿀, 도라지와 감초 혼합 추출물, 도라지와 감국 혼합 추출물, 도라지와 꿀 혼합 추출물, 감초와 감국 혼합 추출물, 감초와 꿀 혼합 추출물, 감국과 꿀 혼합 추출물, 도라지와 감초와 감국 혼합 추출물, 도라지와 감초와 꿀 혼합 추출물, 감초와 감국과 꿀 혼합 추출물 및 도라지와 감초와 감국과 꿀 혼합 추출물의 PM2.5에 의해 유발된 NO 생성을 억제하는 효과를 나타낸 그래프이다.
도 2는 도라지 추출물, 감초 추출물, 감국 추출물, 꿀, 도라지와 감초 혼합 추출물, 도라지와 감국 혼합 추출물, 도라지와 꿀 혼합 추출물, 감초와 감국 혼합 추출물, 감초와 꿀 혼합 추출물, 감국과 꿀 혼합 추출물, 도라지와 감초와 감국 혼합 추출물, 도라지와 감초와 꿀 혼합 추출물, 감초와 감국과 꿀 혼합 추출물 및 도라지와 감초와 감국과 꿀 혼합 추출물의 PM2.5에 의해 유발된 IL-8 생성을 억제하는 효과를 나타낸 그래프이다.
도 3은 도라지 추출물, 감초 추출물, 감국 추출물, 꿀, 도라지와 감초 혼합 추출물, 도라지와 감국 혼합 추출물, 도라지와 꿀 혼합 추출물, 감초와 감국 혼합 추출물, 감초와 꿀 혼합 추출물, 감국과 꿀 혼합 추출물, 도라지와 감초와 감국 혼합 추출물, 도라지와 감초와 꿀 혼합 추출물, 감초와 감국과 꿀 혼합 추출물 및 도라지와 감초와 감국과 꿀 혼합 추출물의 PM2.5에 의해 유발된 TNF-α 생성을 억제하는 효과를 나타낸 그래프이다.1 is a bellflower extract, licorice extract, chrysanthemum extract, honey, bellflower and licorice mixed extract, bellflower and chrysanthemum mixed extract, bellflower and honey mixed extract, licorice and chrysanthemum mixed extract, licorice and honey mixed extract, chrysanthemum and honey mixed extract, Graph showing the effect of inhibiting PM2.5-induced NO production of bellflower, licorice and chrysanthemum mixed extract, bellflower, licorice and honey mixed extract, licorice, chrysanthemum and honey mixed extract, and bellflower, licorice, chrysanthemum and honey mixed extract to be.
Figure 2 is bellflower extract, licorice extract, chrysanthemum extract, honey, bellflower and licorice mixed extract, bellflower and chrysanthemum mixed extract, bellflower and honey mixed extract, licorice and chrysanthemum mixed extract, licorice and honey mixed extract, chrysanthemum and honey mixed extract, The effect of inhibiting PM2.5-induced IL-8 production of bellflower, licorice and chrysanthemum mixed extract, bellflower, licorice and honey mixed extract, licorice, chrysanthemum and honey mixed extract, and bellflower, licorice, chrysanthemum and honey mixed extract This is the graph shown.
Figure 3 is bellflower extract, licorice extract, chrysanthemum extract, honey, bellflower and licorice mixed extract, bellflower and chrysanthemum mixed extract, bellflower and honey mixed extract, licorice and chrysanthemum mixed extract, licorice and honey mixed extract, chrysanthemum and honey mixed extract, The effect of inhibiting PM2.5-induced TNF-α production of bellflower, licorice and chrysanthemum mixed extract, bellflower, licorice and honey mixed extract, licorice, chrysanthemum and honey mixed extract, and bellflower, licorice, chrysanthemum and honey mixed extract This is the graph shown.
본 발명은, 일면에 있어서, 도라지 유효성분을 포함한 천연물 추출물을 유효성분으로 하는 미세먼지 관련 호흡기 질환의 예방 및 치료용 약학적 조성물 및 식품 조성물을 제공한다.The present invention, in one aspect, provides a pharmaceutical composition and a food composition for the prevention and treatment of respiratory diseases related to fine dust, comprising a natural extract including a bellflower active ingredient as an active ingredient.
이하, 본 발명에 따른 미세먼지에 의한 호흡기 질환의 예방 및 치료용 조성물을 첨부된 도면을 참고하여 더욱 상세히 설명한다.Hereinafter, the composition for the prevention and treatment of respiratory diseases caused by fine dust according to the present invention will be described in more detail with reference to the accompanying drawings.
상기 도라지(Platycodon grandiflorus)는 초롱꽃과 도라지속(Platycodon)에 속하는 여러해살이풀이다. 길경이라고도 부르며, 사포닌이 많이 포함되어 있어서 생약으로 이용되고 있다. 그밖에도 칼슘, 섬유질, 철분, 무기질, 단백질, 비타민 등이 함유되어 있다. 거담, 진해, 진통, 진정, 해열 작용이 있으며, 소염진통, 진해거담제로 사용된다.The bellflower ( Platycodon grandiflorus ) is a perennial herb belonging to the bellflower and bellflower genus (Platycodon). It is also called Gilgyeong and contains a lot of saponins, so it is used as a herbal medicine. In addition, it contains calcium, fiber, iron, minerals, protein, and vitamins. It has expectorant, antitussive, analgesic, sedative, and antipyretic action, and is used as an anti-inflammatory analgesic and antitussive expectorant.
상기 감초(Glycyrrhiza uralensis)는 콩과에 속하는 여러해살이풀로 중국 북동부와 시베리아, 몽골, 중국 북부 등지에 분포한다. 뿌리는 건조시켜서 한약재로 사용하는데, 그 맛이 달고, 모든 약물과 배합이 잘 되어 중화작용을 한다.The licorice ( Glycyrrhiza uralensis ) is a perennial plant belonging to the legume family and is distributed in northeastern China, Siberia, Mongolia, and northern China. The roots are dried and used as herbal medicines, and they have a sweet taste and are well combined with all drugs to neutralize.
상기 감국(Chrysanthemum indicum)은 국화과의 여러해살이풀이며, 말린 꽃잎은 소주에 넣어 감국주를 만들거나 한약재로 쓰는데 기침약, 해열제, 항균제, 혈압강하제로 사용된다.The Gamguk ( Chrysanthemum indicum ) is a perennial herb of the Asteraceae family, and dried petals are put in soju to make Gamgukju or used as a herbal medicine, and are used as cough medicine, antipyretic agent, antibacterial agent, and blood pressure lowering agent.
상기 꿀(Honey)는 자연이 제공하는 천연 설탕으로, 면역체계 자극, 체중 감량, 심장 질환 감소, 소화불량 완화, 피로감 감소 및 피부 트러블 감소 등의 효능이 있는 것으로 알려져있다.The honey (Honey) is a natural sugar provided by nature, and is known to have effects such as stimulation of the immune system, weight loss, reduction of heart disease, alleviation of indigestion, reduction of fatigue and reduction of skin troubles.
상기 추출물은 물, C1 내지 C4의 저급 알코올 또는 이들의 혼합 용매로 추출하여 수득할 수 있으며, 상기 저급 알코올은 에탄올 또는 메탄올일 수 있고, 보다 구체적으로 에탄올일 수 있다.The extract may be obtained by extraction with water, a C1 to C4 lower alcohol or a mixed solvent thereof, and the lower alcohol may be ethanol or methanol, and more specifically, ethanol.
본 발명에 대한 도라지와 감초와 감국 및 꿀의 복합 추출물은 후술하는 시험예에서 확인되는 바와 같이 미세먼지에 의한 NO 생성 억제율 시험에서 62%까지 억제하였고, 미세먼지 자극에 의한 폐조직내 염증성 Cytokine인 IL-8의 발현양의 증가를 크게 감소시켰다. 또한, TNF-α의 생성 억제율이 61%까지 억제하였다.The complex extract of bellflower, licorice, chrysanthemum and honey for the present invention inhibited up to 62% in the NO production inhibition rate test by fine dust, as confirmed in the test examples to be described later, and was an inflammatory cytokine in lung tissue caused by fine dust stimulation. The increase in the expression level of IL-8 was greatly reduced. In addition, the inhibition rate of TNF-α production was inhibited by 61%.
본 발명은 상기 제조방법으로 제조된 도라지 유효성분을 포함한 천연물 추출물을 유효성분으로 하는 미세먼지 관련 호흡기 질환의 예방 및 치료용 약학 조성물을 제공한다.The present invention provides a pharmaceutical composition for the prevention and treatment of fine dust-related respiratory diseases comprising, as an active ingredient, a natural product extract including an active ingredient of bellflower prepared by the above preparation method.
상기 천연물 추출물을 조성물 총 100 중량부에 대하여 0.01 내지 100 중량부로 포함될 수 있으나, 이에 제한되는 것은 아님을 명시한다.The natural extract may be included in an amount of 0.01 to 100 parts by weight based on 100 parts by weight of the total composition, but is not limited thereto.
본 발명의 조성물이 약학 조성물인 경우, 투여를 위하여, 상기 기재한 유효성분 이외에 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 포함할 수 있다. 상기 담체, 부형제 및 희석제로는 락토오스, 덱스트로오스, 수크로오스, 소르비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.When the composition of the present invention is a pharmaceutical composition, for administration, a pharmaceutically acceptable carrier, excipient or diluent may be included in addition to the active ingredients described above. The carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
본 발명의 약학 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 또는 멸균 주사용액의 형태로 제형화하여 사용할 수 있다. 상세하게는 제형화할 경우 통상 사용하는 충진제, 중량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형 제제로는 정제, 환제, 산제, 과립제, 캡슐제 등을 포함하나, 이에 한정되는 것은 아니다. 이러한 고형 제제는 상기 유효성분 외에 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘 카보네이트, 수크로오스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등을 첨가하여 조제될 수 있다. 비경구 투여를 위한 제제는 멸균된 수용액, 비수성 용제, 현탁제, 유제, 동결건조 제제 및 과제를 포함한다. 비수성 용제 및 현탁제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 오일, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔, 마크로솔, 트윈 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The pharmaceutical composition of the present invention can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, or sterile injection solutions, respectively, according to conventional methods. . In detail, when formulating, it may be prepared using a diluent or excipient such as a filler, a weight agent, a binder, a wetting agent, a disintegrant, and a surfactant commonly used. Solid preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. Such a solid preparation may be prepared by mixing at least one or more excipients, for example, starch, calcium carbonate, sucrose, lactose, gelatin, etc. in addition to the active ingredient. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. It can be prepared by adding various excipients, for example, wetting agents, sweetening agents, fragrances, preservatives, and the like, in addition to liquids for oral use and liquid paraffin. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations and tasks. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As the base of the suppository, Witepsol, Macrosol, Tween 61, cacao butter, laurin fat, glycerogelatin, etc. can be used.
본 발명의 약학 조성물의 적합한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 시간에 따라 다르지만, 당 업자에 의해 적절하게 선택될 수 있는 바, 상기 조성물의 일일 투여량은 바람직하게는 0.001 mg/kg 내지 50 mg/kg이며, 필요에 따라 일일 1회 내지 수회로 나누어 투여할 수 있다.A suitable dosage of the pharmaceutical composition of the present invention varies depending on the patient's condition and weight, the degree of disease, drug form, and time, but may be appropriately selected by those skilled in the art, and the daily dosage of the composition is preferably It is 0.001 mg/kg to 50 mg/kg, and may be administered once or several times a day as needed.
또한, 본 발명은 상기 제조방법으로 제조된 도라지 유효성분을 포함한 천연물 추출물을 유효성분으로 하는 미세먼지 관련 호흡기 질환의 예방 및 치료용 식품 조성물을 제공한다.In addition, the present invention provides a food composition for the prevention and treatment of respiratory diseases related to fine dust, comprising, as an active ingredient, a natural product extract including an active ingredient of bellflower prepared by the above manufacturing method.
상기 천연물 추출물을 조성물 총 100 중량부에 대하여 0.01 내지 100 중량부로 포함될 수 있으나, 이에 제한되는 것은 아님을 명시한다.The natural extract may be included in an amount of 0.01 to 100 parts by weight based on 100 parts by weight of the total composition, but is not limited thereto.
본 발명의 조성물이 건강식품 조성물인 경우, 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일 주스, 합성 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 또한, 건강식품 조성물은 육류, 소세지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 껌류, 아이스크림류, 스프, 음료수, 차, 기능수, 드링크제, 알코올 및 비타민 복합제 중 어느 하나의 형태일 수 있다.When the composition of the present invention is a health food composition, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and salts thereof , alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, it may contain the pulp for the production of natural fruit juices, synthetic fruit juices and vegetable beverages. These components may be used independently or in combination. In addition, the health food composition may be in the form of any one of meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, drink, alcohol and vitamin complex. can
또한, 상기 건강식품 조성물은 식품첨가물을 추가로 포함할 수 있으며, 식품첨가물로서의 적합 여부는 다른 규정이 없는 한 식품의약품안전처에 승인된 식품첨가물공전의 총칙 및 일반 시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.In addition, the health food composition may additionally contain food additives, and the suitability as a food additive is determined according to the general rules and general test methods of the Food Additives Code approved by the Ministry of Food and Drug Safety, unless otherwise specified. It is judged according to the standards and standards.
상기 식품첨가물공전에 수재된 품목으로 예를 들어, 케톤류, 글리신, 구연산 칼륨, 니코틴산, 계피산 등의 화학적 합성품, 감색소, 감초추출물, 결정셀룰로오스, 고랭색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류 첨가 알칼리제, 보존료제제, 타르색소 제제 등의 혼합 제제류 등을 들 수 있다.Items listed in the Food Additives Codex, for example, chemically synthesized products such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid; Mixed preparations, such as a sodium preparation, an alkali agent for noodles, a preservative preparation, and a tar dye preparation, etc. are mentioned.
이때, 건강식품 조성물을 제조하는 과정에서 식품에 첨가되는 본 발명에 따른 조성물은 필요에 따라 그 함량을 적절히 가감할 수 있다.In this case, the composition according to the present invention to be added to food in the process of preparing the health food composition may appropriately increase or decrease its content as needed.
이하에서는 실시예 등을 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through examples and the like. These examples are only for illustrating the present invention in more detail, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. .
실시예 1: 도라지와 감초와 감국 및 꿀 혼합 추출물의 제조Example 1: Preparation of bellflower, licorice, chrysanthemum and honey mixed extract
건조 분쇄된 도라지와 감초와 감국 및 꿀 각각 20g 혼합한 후, 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 800 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 도라지와 감초와 감국 및 꿀 혼합 추출물 34%의 수율로 수득하였다.After mixing 20 g each of dried and pulverized bellflower, licorice, chrysanthemum and honey, 800 ml of 70% ethanol mixed with purified water and ethanol in a volume ratio of 30:70, respectively, was added and extracted by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol, and then freeze-dried to obtain a 34% yield of a mixed extract of bellflower, licorice, chrysanthemum and honey.
비교예 1: 도라지 추출물의 제조Comparative Example 1: Preparation of bellflower extract
건조 분쇄된 도라지 80g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 800 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 도라지 추출물 35%의 수율로 수득하였다.To 80 g of dried and pulverized bellflower, 800 ml of 70% ethanol mixed with purified water and ethanol at a volume ratio of 30:70, respectively, was added, and extracted by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol, and then freeze-dried to obtain a bellflower extract in a yield of 35%.
비교예 2: 감초 추출물의 제조Comparative Example 2: Preparation of licorice extract
건조 분쇄된 감초 80g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 800 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 감초 추출물 35%의 수율로 수득하였다.To 80 g of dry and pulverized licorice, 800 ml of 70% ethanol mixed with purified water and ethanol in a volume ratio of 30:70, respectively, was added, and extracted by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol and then freeze-dried to obtain a licorice extract in a yield of 35%.
비교예 3: 감국 추출물의 제조Comparative Example 3: Preparation of chrysanthemum extract
건조 분쇄된 감국 80g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 800 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 감국 추출물 34%의 수율로 수득하였다.80 g of dried and pulverized chrysanthemum was added to 800 ml of 70% ethanol mixed with purified water and ethanol in a volume ratio of 30:70, respectively, and extracted by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol and then freeze-dried to obtain a chrysanthemum extract in a yield of 34%.
비교예 4: 꿀 추출물의 제조Comparative Example 4: Preparation of honey extract
건조 분쇄된 꿀 80g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 800 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 꿀 추출물 32%의 수율로 수득하였다.80 g of dry ground honey was added with 800 ml of 70% ethanol mixed with purified water and ethanol in a volume ratio of 30:70, respectively, and extracted by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol and then freeze-dried to obtain a honey extract in a yield of 32%.
비교예 5: 도라지 및 감초 혼합 추출물의 제조Comparative Example 5: Preparation of bellflower and licorice mixed extract
건조 분쇄된 도라지 및 감초(중량비 1:1로 혼합) 40g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 800 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 도라지 및 감초 혼합 추출물 33%의 수율로 수득하였다.To 40 g of dried and pulverized bellflower and licorice (mixed at a weight ratio of 1:1), 800 ml of 70% ethanol obtained by mixing purified water and ethanol at a volume ratio of 30:70, respectively, was added, followed by extraction by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol, and then freeze-dried to obtain a mixed extract of bellflower and licorice in a yield of 33%.
비교예 6: 도라지 및 감국 혼합 추출물의 제조Comparative Example 6: Preparation of bellflower and chrysanthemum mixed extract
건조 분쇄된 도라지 및 감국(중량비 1:1로 혼합) 40g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 800 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 도라지 및 감국 혼합 추출물 34%의 수율로 수득하였다.To 40 g of dried and pulverized bellflower and chrysanthemum (mixed in a weight ratio of 1:1), 800 ml of 70% ethanol mixed with purified water and ethanol in a volume ratio of 30:70, respectively, was added, and extracted by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol and then freeze-dried to obtain a mixed extract of bellflower and chrysanthemum in a yield of 34%.
비교예 7: 도라지 및 꿀 혼합 추출물의 제조Comparative Example 7: Preparation of bellflower and honey mixed extract
건조 분쇄된 도라지 및 꿀(중량비 1:1로 혼합) 40g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 800 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 도라지 및 꿀 혼합 추출물 34%의 수율로 수득하였다.To 40 g of dried and pulverized bellflower and honey (mixed in a weight ratio of 1:1), 800 ml of 70% ethanol obtained by mixing purified water and ethanol in a volume ratio of 30:70, respectively, was added, followed by extraction by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol, and then freeze-dried to obtain a mixed extract of bellflower and honey in a yield of 34%.
비교예 8: 감초 및 감국 혼합 추출물의 제조Comparative Example 8: Preparation of licorice and chrysanthemum mixed extract
건조 분쇄된 감초 및 감국(중량비 1:1로 혼합) 40g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 800 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 감초 및 감국 혼합 추출물 33%의 수율로 수득하였다.To 40 g of dry pulverized licorice and chrysanthemum (mixed in a weight ratio of 1:1), 800 ml of 70% ethanol mixed with purified water and ethanol in a volume ratio of 30:70, respectively, was added, followed by extraction by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol and then freeze-dried to obtain a mixed extract of licorice and chrysanthemum in a yield of 33%.
비교예 9: 감초 및 꿀 혼합 추출물의 제조Comparative Example 9: Preparation of licorice and honey mixed extract
건조 분쇄된 감초 및 꿀(중량비 1:1로 혼합) 40g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 800 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 감초 및 꿀 혼합 추출물 34%의 수율로 수득하였다.To 40 g of dry pulverized licorice and honey (mixed in a weight ratio of 1:1), 800 ml of 70% ethanol mixed with purified water and ethanol in a volume ratio of 30:70, respectively, was added, and extracted by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol and then freeze-dried to obtain a mixed extract of licorice and honey in a yield of 34%.
비교예 10: 감국 및 꿀 혼합 추출물의 제조Comparative Example 10: Preparation of mixed extract of chrysanthemum and honey
건조 분쇄된 감국 및 꿀(중량비 1:1로 혼합) 40g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 800 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 감국 및 꿀 혼합 추출물 35%의 수율로 수득하였다.To 40 g of dry pulverized chrysanthemum and honey (mixed at a weight ratio of 1:1), 800 ml of 70% ethanol mixed with purified water and ethanol at a volume ratio of 30:70, respectively, was added, followed by extraction by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol, and then freeze-dried to obtain a 35% yield of a mixed extract of chrysanthemum and honey.
비교예 11: 도라지와 감초 및 감국 혼합 추출물의 제조Comparative Example 11: Preparation of bellflower, licorice and chrysanthemum mixed extract
건조 분쇄된 도라지와 감초 및 감국(중량비 1:1로 혼합) 27g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 800 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 도라지와 감초 및 감국 혼합 추출물 36%의 수율로 수득하였다.To 27 g of dried and pulverized bellflower, licorice and chrysanthemum (mixed in a weight ratio of 1:1), 800 ml of 70% ethanol mixed with purified water and ethanol in a volume ratio of 30:70, respectively, was added, and extracted by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol, and then freeze-dried to obtain a 36% yield of a mixed extract of bellflower, licorice and chrysanthemum.
비교예 12: 도라지와 감초 및 꿀 혼합 추출물의 제조Comparative Example 12: Preparation of bellflower, licorice and honey mixed extract
건조 분쇄된 도라지와 감초 및 꿀(중량비 1:1로 혼합) 27g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 800 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 도라지와 감초 및 꿀 혼합 추출물 33%의 수율로 수득하였다.To 27 g of dried and pulverized bellflower, licorice and honey (mixed at a weight ratio of 1:1), 800 ml of 70% ethanol mixed with purified water and ethanol at a volume ratio of 30:70, respectively, was added, followed by extraction by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol, and then freeze-dried to obtain a mixed extract of bellflower, licorice and honey in a yield of 33%.
비교예 13: 도라지와 감국 및 꿀 혼합 추출물의 제조Comparative Example 13: Preparation of a mixed extract of bellflower, chrysanthemum and honey
건조 분쇄된 도라지와 감국 및 꿀(중량비 1:1로 혼합) 27g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 800 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 도라지와 감국 및 꿀 혼합 추출물 35%의 수율로 수득하였다.To 27 g of dried and pulverized bellflower, chrysanthemum and honey (mixed at a weight ratio of 1:1), 800 ml of 70% ethanol mixed with purified water and ethanol at a volume ratio of 30:70, respectively, was added, followed by extraction by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol and then freeze-dried to obtain a 35% yield of a mixed extract of bellflower, chrysanthemum and honey.
비교예 14: 감초와 감국 및 꿀 혼합 추출물의 제조Comparative Example 14: Preparation of mixed extract of licorice, chrysanthemum and honey
건조 분쇄된 감초와 감국 및 꿀(중량비 1:1로 혼합) 27g을 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 800 ml 가하고 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 감초와 감국 및 꿀 혼합 추출물 35%의 수율로 수득하였다.To 27 g of dry pulverized licorice, chrysanthemum and honey (mixed in a weight ratio of 1:1), 800 ml of 70% ethanol mixed with purified water and ethanol in a volume ratio of 30:70, respectively, was added, followed by extraction by heating at 100° C. for 6 hours. The extract was filtered and concentrated under reduced pressure to remove ethanol, and then freeze-dried to obtain a 35% yield of a mixed extract of licorice, chrysanthemum and honey.
시험예 1: 도라지와 감초와 감국 및 꿀 추출물의 세포독성 확인Test Example 1: Confirmation of cytotoxicity of bellflower, licorice, chrysanthemum and honey extracts
도라지와 감초와 감국 및 꿀 추출물이 세포독성이 있는지 여부를 확인하기 위하여 다음과 같은 방법으로 실험하였다. Raw 264.7 cell 및 B2B(BEAS-2B) cell을 6.0 x 104 cells/well로 분주한 후 24시간 동안 37℃, 5% CO2 조건에서 배양하였다. 실시예 1과 비교예 1 내지 14의 추출물을 50~1,000 ㎍/ml의 농도로 처리하고 24시간 후 MTT 용액을 가하고 37℃에서 4시간 더 배양하여 생성된 formazan이 배지에 떨어져 나가지 않도록 배지를 제거하고 DMSO 100 ㎕ 분주하여 10분 동안 혼합한 후 540 nm에서 흡광도를 측정함으로써 세포 생존율을 확인하였으며, 도라지와 감초와 감국 및 꿀 추출물에 대한 결과를 하기 표 1 내지 표 2에 나타내었다.To determine whether bellflower, licorice, chrysanthemum, and honey extracts were cytotoxic, the following experiment was conducted. Raw 264.7 cells and B2B (BEAS-2B) cells were seeded at 6.0 x 10 4 cells/well and cultured at 37° C. and 5% CO 2 conditions for 24 hours. The extracts of Example 1 and Comparative Examples 1 to 14 were treated at a concentration of 50 to 1,000 μg/ml, and after 24 hours, MTT solution was added and cultured at 37° C. for 4 more hours to remove the medium so that the formed formazan does not fall off the medium. Then, 100 μl of DMSO was dispensed, mixed for 10 minutes, and the cell viability was checked by measuring absorbance at 540 nm.
하기 표 1 내지 표 2에 나타난 바와 같이, 도라지와 감초와 감국 및 꿀 추출물은 50 내지 400 ㎍/ml에서 세포 독성이 나타나지 않음을 확인하였다.As shown in Tables 1 and 2 below, it was confirmed that bellflower, licorice, chrysanthemum and honey extracts did not show cytotoxicity at 50 to 400 μg/ml.
시험예 2: 도라지와 감초와 감국 및 꿀 추출물의 NO 생성 억제능 평가 Test Example 2: Evaluation of NO production inhibitory ability of bellflower, licorice, chrysanthemum and honey extracts
상기 시험예 1에서 확인한 도라지와 감초와 감국 및 꿀 추출물을 세포독성이 없는 농도인 100~400 ㎍/ml로 처리하여 NO 생성능 억제능을 다음과 같은 방법으로 평가하였다. The NO-producing ability inhibitory ability was evaluated in the following manner by treating the extracts of bellflower, licorice, chrysanthemum and honey confirmed in Test Example 1 at a concentration of 100 to 400 μg/ml, which is non-cytotoxic.
Raw 264.7 cell을 96 well plate에 6 x 104 cells/well로 분주한 후, 24시간 동안 37℃, 5% CO2 조건에서 배양하였다. 도라지와 감초와 감국 및 꿀 추출물을 100, 200, 400 ㎍/ml의 농도로 처리하고 미세먼지 표준품을 처리한 후, 다시 24시간 동안 배양하였다. 그 후 세포 배양액을 Griess reagent와 1:1로 혼합하고 540 nm에서 흡광도를 측정하여 NO 생성을 측정하였고, 그 결과를 도 1에 나타내었다.Raw 264.7 cells were seeded in a 96-well plate at 6 x 10 4 cells/well, and then cultured at 37°C and 5% CO 2 conditions for 24 hours. Bellflower, licorice, chrysanthemum and honey extracts were treated at concentrations of 100, 200, and 400 μg/ml, treated with fine dust standards, and then cultured for 24 hours again. Thereafter, the cell culture solution was mixed with Griess reagent 1:1 and absorbance was measured at 540 nm to measure NO production, and the results are shown in FIG. 1 .
도 1에 나타낸 바와 같이, 도라지와 감초와 감국 및 꿀 추출물은 농도 의존적으로 NO 생성 억제 효과를 나타내었고, 하나의 추출물만 처리하였을 때보다 혼합 추출물이 더 우수한 NO 생성 억제 효과를 나타내었다.As shown in FIG. 1, the extracts of bellflower, licorice, chrysanthemum and honey exhibited a concentration-dependent inhibitory effect on NO production, and the mixed extract exhibited a better inhibitory effect on NO production than when only one extract was treated.
시험예 3: 도라지와 감초와 감국 및 꿀 추출물의 IL-8 생성 억제능 평가Test Example 3: Evaluation of IL-8 production inhibitory ability of bellflower, licorice, chrysanthemum and honey extracts
상기 시험예 1에서 확인한 도라지와 감초와 감국 및 꿀 추출물을 세포독성이 없는 농도인 100~400 ㎍/ml로 처리하여 IL-8 생성 억제능을 다음과 같은 방법으로 평가하였다.The ability to inhibit IL-8 production was evaluated by treating the extracts of bellflower, licorice, chrysanthemum, and honey confirmed in Test Example 1 at a concentration of 100 to 400 μg/ml, which is non-cytotoxic.
96 well plate에 B2B cell을 6 x 104 cells/well로 분주한 후, 24시간 동안 37℃, 5% CO2 조건에서 배양하였다. 도라지와 감초와 감국 및 꿀 추출물을 100, 200, 400 ㎍/ml의 농도로 처리하고 미세먼지 표준품을 처리한 후, 다시 24시간 동안 배양하였다. 그 후 세포 배양액을 취하여 IL-8의 정량에 대한 ELISA kit를 이용하여 정량하였으며, 도라지와 감초와 감국 및 꿀 추출물에 대한 결과를 도 2에 나타내었다.B2B cells were seeded in a 96-well plate at 6 x 10 4 cells/well, and then cultured at 37° C. and 5% CO 2 conditions for 24 hours. Bellflower, licorice, chrysanthemum and honey extracts were treated at concentrations of 100, 200, and 400 μg/ml, treated with fine dust standards, and then cultured for 24 hours again. After that, the cell culture medium was taken and quantified using an ELISA kit for quantification of IL-8, and the results for bellflower, licorice, chrysanthemum and honey extracts are shown in FIG. 2 .
도 2에 나타낸 바와 같이, 도라지와 감초와 감국 및 꿀 추출물은 농도 의존적으로 IL-8 생성 억제효과를 나타내었고, 하나의 추출물만 처리하였을 때보다 혼합 추출물이 더 우수한 억제 효과를 나타내었다.As shown in FIG. 2 , the extracts of bellflower, licorice, chrysanthemum and honey showed a concentration-dependent inhibitory effect on IL-8 production, and the mixed extract showed a better inhibitory effect than when only one extract was treated.
시험예 4: 도라지와 감초와 감국 및 꿀 추출물의 TNF-α 생성 억제능 평가Test Example 4: Evaluation of TNF-α production inhibitory ability of bellflower, licorice, chrysanthemum and honey extracts
상기 시험예 1에서 확인한 도라지와 감초와 감국 및 꿀 추출물을 세포독성이 없는 농도인 100~400 ㎍/ml로 처리하여 TNF-α 생성 억제능을 다음과 같은 방법으로 평가하였다.The TNF-α production inhibitory ability was evaluated by treating the extracts of bellflower, licorice, chrysanthemum and honey confirmed in Test Example 1 at a concentration of 100 to 400 μg/ml without cytotoxicity.
96 well plate에 B2B cell을 6 x 104 cells/well로 분주한 후, 24시간 동안 37℃, 5% CO2 조건에서 배양하였다. 도라지와 감초와 감국 및 꿀 추출물을 100, 200, 400 ㎍/ml의 농도로 처리하고 미세먼지 표준품을 처리한 후, 다시 24시간 동안 배양하였다. 그 후 세포 배양액을 취하여 TNF-α의 정량에 대한 ELISA kit를 이용하여 정량하였으며, 도라지와 감초와 감국 및 꿀 추출물에 대한 결과를 도 3에 나타내었다.B2B cells were seeded in a 96-well plate at 6 x 10 4 cells/well, and then cultured at 37° C. and 5% CO 2 conditions for 24 hours. Bellflower, licorice, chrysanthemum and honey extracts were treated at concentrations of 100, 200, and 400 μg/ml, treated with fine dust standards, and then cultured for 24 hours again. After that, the cell culture medium was taken and quantified using an ELISA kit for quantification of TNF-α, and the results for bellflower, licorice, chrysanthemum and honey extracts are shown in FIG. 3 .
도 3에 나타낸 바와 같이, 도라지와 감초와 감국 및 꿀 추출물은 농도 의존적으로 TNF-α 생성 억제효과를 나타내었고, 하나의 추출물만 처리하였을 때보다 혼합 추출물이 더 우수한 억제 효과를 나타내었다.As shown in Figure 3, bellflower, licorice, chrysanthemum and honey extracts showed a concentration-dependent TNF-α production inhibitory effect, and the mixed extract showed a better inhibitory effect than when only one extract was treated.
Claims (7)
상기 도라지(Platycodon grandiflorus) 추출물, 감초(Glycyrrhiza uralensis) 추출물, 감국(Chrysanthemum indicum) 추출물 및 꿀(Honey) 추출물의 혼합된 추출물은, 도라지, 감초, 감국 및 꿀을 각각 20g씩 혼합한 후, 70% 에탄올을 800㎖ 투입하고, 100℃로 6시간 동안 가온 추출한 추출액을 여과, 감압 및 농축하여 상기 투입된 에탄올을 제거 및 동결 건조하여 34%의 수율로 수득한 도라지(Platycodon grandiflorus) 추출물, 감초(Glycyrrhiza uralensis) 추출물, 감국(Chrysanthemum indicum) 추출물 및 꿀(Honey) 추출물의 혼합된 추출물로서, NO 생성을 억제하고, 염증성 사이토카인 IL-8과 TNF-α 생성을 억제하는 것을 특징으로 하는, 미세먼지에 의한 기관지 염증 질환의 개선용 건강 기능 식품 조성물.
A health functional food composition for improving bronchial inflammatory diseases caused by fine dust comprising a mixed extract of a bellflower (Platycodon grandiflorus) extract, licorice (Glycyrrhiza uralensis) extract, Chrysanthemum indicum extract and honey extract as an active ingredient In
The bellflower (Platycodon grandiflorus) extract, licorice (Glycyrrhiza uralensis) extract, chrysanthemum (Chrysanthemum indicum) extract and honey (Honey) extract mixed extract, bellflower, licorice, chrysanthemum and honey after mixing 20 g each, 70% 800 ml of ethanol was added, and the extracted extract heated at 100° C. for 6 hours was filtered, reduced pressure and concentrated to remove the added ethanol and freeze-dried to obtain a 34% yield of bellflower (Platycodon grandiflorus) extract, Glycyrrhiza uralensis. ) extract, a mixed extract of Chrysanthemum indicum extract and honey extract, characterized in that it suppresses NO production and inhibits the production of inflammatory cytokines IL-8 and TNF-α. A health functional food composition for the improvement of bronchial inflammatory diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200028725A KR102355106B1 (en) | 2020-03-08 | 2020-03-08 | Pharmaceutical and functional food composition comprising complex extract of Platycodon grandiflorus for prevention or treatment of respiratory disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200028725A KR102355106B1 (en) | 2020-03-08 | 2020-03-08 | Pharmaceutical and functional food composition comprising complex extract of Platycodon grandiflorus for prevention or treatment of respiratory disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210117363A KR20210117363A (en) | 2021-09-29 |
| KR102355106B1 true KR102355106B1 (en) | 2022-01-26 |
Family
ID=77924628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200028725A KR102355106B1 (en) | 2020-03-08 | 2020-03-08 | Pharmaceutical and functional food composition comprising complex extract of Platycodon grandiflorus for prevention or treatment of respiratory disease |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102355106B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019078370A1 (en) | 2017-10-20 | 2019-04-25 | ロート製薬株式会社 | Composition for ameliorating skin disorders |
| KR102131602B1 (en) | 2020-02-19 | 2020-07-08 | 코스맥스엔비티 주식회사 | A composition for the prevention or treatment of respiratory diseases caused by fine dust containing agastache rugosa and licorice extract |
| KR102188416B1 (en) | 2019-07-10 | 2020-12-08 | 대전대학교 산학협력단 | Complex Medicines for Improving Respiratory Inflammation Caused Fine Dust |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101715274B1 (en) * | 2014-07-03 | 2017-03-13 | 원광대학교산학협력단 | Composition containing extract or fractions of Chrysanthemum indicum L. for treating, improving or preventing inflammatory disease |
| KR20180055038A (en) * | 2016-11-16 | 2018-05-25 | 동신대학교산학협력단 | Composition for treating asthma comprising Platycodon grandiflorum extract |
| KR102134385B1 (en) | 2017-02-06 | 2020-07-16 | 주식회사 한국인삼공사 | Composition for Respiratory Symptoms Containing Red Ginseng Extract |
-
2020
- 2020-03-08 KR KR1020200028725A patent/KR102355106B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019078370A1 (en) | 2017-10-20 | 2019-04-25 | ロート製薬株式会社 | Composition for ameliorating skin disorders |
| KR102188416B1 (en) | 2019-07-10 | 2020-12-08 | 대전대학교 산학협력단 | Complex Medicines for Improving Respiratory Inflammation Caused Fine Dust |
| KR102131602B1 (en) | 2020-02-19 | 2020-07-08 | 코스맥스엔비티 주식회사 | A composition for the prevention or treatment of respiratory diseases caused by fine dust containing agastache rugosa and licorice extract |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210117363A (en) | 2021-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20120133133A (en) | Composition for Prevention or Treatment of Respiratory Disease Comprising Herbal Extract and Fermentation Product thereof with Lactic acid Bacteria | |
| KR100771524B1 (en) | Composition for improving liver function comprising herbal mixture extract | |
| WO2015046486A1 (en) | Anti-obesity composition | |
| KR102169920B1 (en) | A composition comprising extract of Schisandra chinensis, pear and Platycodon grandiflorum for preventing or treating respiratory inflammatory diseases | |
| KR102366919B1 (en) | Functional health food composition for inhibiting muscle reduction comprising a mixed extract of mulberry twig, Eucommia bark, Acanthopanax, and black bean | |
| KR100771525B1 (en) | Composition for removing hangover comprising herbal mixture extract | |
| KR101416191B1 (en) | Pharmaceutical composition for preventing or treating cancer comprising extract of Jeju traditional citrus Palsac, Dangyusa or Iyegam as effective component | |
| KR102355106B1 (en) | Pharmaceutical and functional food composition comprising complex extract of Platycodon grandiflorus for prevention or treatment of respiratory disease | |
| KR100462788B1 (en) | Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory | |
| KR102355104B1 (en) | Pharmaceutical and functional food composition comprising complex extract of Brassica rapa for prevention or treatment of respiratory disease | |
| KR20230134378A (en) | Pharmaceutical composition for the prevention or treatment diseases related to muscle loss comprising a mixed plant extract powder as an active ingredient | |
| KR102297398B1 (en) | Composition for health food for improving of respiratory diseases caused by fine dust comprising extract of Liriope platyphylla, Glycyrrhiza uralensis and Aronia as an effective component | |
| KR20150063905A (en) | Compositions for preventing or improving of alcoholic liver disease, or reducing alcoholic hangup comprising Rosa rugosa extracts | |
| KR102098928B1 (en) | Composition for enhancing immunituy for fine response using balloonflower and pear mixed liquid | |
| KR101520417B1 (en) | Composition comprising herbal mixture extract for treating or preventing thyroid cancer | |
| KR101483585B1 (en) | Composition comprising complex extract of Astragalus Membranaceus, Schisandra Chinesis and Platycodon grandiflorum for preventing or treating inflammatory disease | |
| KR20050100890A (en) | Composition comprising the extract of acanthopanax sessiliflorus and green tea for treating or alleviating hangover syndrome | |
| KR101131719B1 (en) | Pulsatilla koreana extracts compositions for treating or preventing inflammatory diseases | |
| KR101282356B1 (en) | Composition comprising Acanthopanacis Cortex butanol fraction for preventing or treating gastrointestinal disease | |
| KR102651713B1 (en) | Chocolate composition for relieving hangovers comprising Hovenia Dulcis fruit and Velvet Antlers, and the manufacturing method of chocolate for relieving hangovers using the same | |
| KR20200093227A (en) | Composition for rerpessing smoking and health functional food containing the composition | |
| KR102542119B1 (en) | Composition for preventing or treating inflammatory airway diseases caused fine dust comprising syneilesis aconitifolia (bunge) maxim extract | |
| KR101596006B1 (en) | Composition for Prevention and Treatment of Cardiovascular Diseases | |
| KR20130082249A (en) | Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract | |
| KR102087165B1 (en) | Pharmaceutical composition for Anti-oxidative or Anti-inflammatory comprising extract processed by Enzymatic hydrolysis of the Bark of Eleutherococcus sessiliflorus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) |